Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a report issued on Monday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 3.5 %

Shares of LPCN stock opened at $3.53 on Monday. The stock has a market capitalization of $18.89 million, a P/E ratio of -4.64 and a beta of 1.23. The firm’s 50 day moving average is $4.69 and its 200 day moving average is $4.68. Lipocine has a 12 month low of $3.20 and a 12 month high of $11.79.

Institutional Trading of Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in Lipocine Inc. (NASDAQ:LPCN) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent reporting period. Institutional investors own 9.11% of the company’s stock.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.